Untitled Page

Richard N. Re, MD, FACP

menu top
Richard N. Re
    menu bottom

    Scientific Director, Ochsner Clinic Foundation

    Ochsner Clinic Foundation, 5th Floor, Brent House
    1514 Jefferson Highway, New Orleans, LA  70121
    504-842-3700   |  rre@ochsner.org  

    Past Appointments

    • Head, Section of Hypertensive Diseases, Ochsner Clinic, New Orleans, LA., 1981-2005
    • Vice President, Director of Research, Alton Ochsner Medical Foundation, New Orleans, LA., 1985-2001
    • Vice President, Director of Research, Ochsner Clinic Foundation, New Orleans, LA., 2001-2004
    • Head, Division of Hypertension, Department of Cardiology, Ochsner Clinic Foundation, New Orleans, LA., 2005-2010

    Education/Training

    • A.B., Summa Cum Laude, Harvard College, Cambridge, MA, 1965
    • MD, Cum Laude, Harvard Medical School, Boston, MA, 1969

    Research Interests

    • Cost benefit analysis of health care, bio-medical technology, and pharmaceuticals
    • Improving the definition and measurement of the outcomes of health care
    • The cellular biology of peptide hormones and, in particular, their intracrine actions.

    Selected Publications

    • Re RN, Cook JL. Noncanonical Intracrine Action. J Am Soc Hypertens 2011, Sept 2. [Epub ahead of print]
    • Vitko JR, Re RN, Alam J, Cook JL.  Cell-Penetrating Peptides corresponding to the Angiotensin II Type 1 Receptor Reducer Receptor Accumulation and Cell Surface Expressive and Signaling.  Am J Hypertens. In press 2011, Sept 8 [Epub ahead of print]
    • Krousel-Wood M, Joyce C, Holt E, Muntler P, Webber LS, Morisky DE, Frohlich ED, Re RN.  Predictors of Decline in Medication Adherence: Results from the Cohort Study of Medication Adherence Among Older Adults.  Hypertension 2011; 58:804-810.
    • Stanley E, Muntner P, Re RN, Frohlich ED, Holt E, Krousel-Wood MA.  Quality of life in hypertensive clinic patients following Hurricane Katrina. Ochsner Journal 2011, 11:226-31.
    • Cook JL, Re RN.  Lessons from in-vitro studies and a related intracellular angiotensin II transgenic mouse model. Am J Physiol Regal Integr Comp Physiol. 2011, Dec.14. [Epud ahead of print].
    • Re RN, Cook JL. Could additional inhibitors of the rennin-angiotensin system be clinically useful? Current Hypertension Reviews, 2012, 8:2-8.

    Blue Arrow Curriculum Vitae

    menu top
    Left Menu Home Small
    Left Menu CTU Small
    Left Menu Leadership Small
    Left Menu Give Small
    Left Menu Contact Small
    Left Menu UQ
    menu bottom
    Untitled Page